深圳市卫光生物制品股份有限公司关于向特定对象发行股票审核问询函回复及募集说明书等申请文件更新的提示性公告

Group 1 - The company, Shenzhen Weiguang Biological Products Co., Ltd., received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a specific object issuance of A-shares on October 28, 2025 [1] - The company, along with relevant intermediaries, conducted a thorough review and response to the questions raised in the inquiry letter, updating the content of the fundraising prospectus and related application documents accordingly [1] - The financial data in the fundraising documents was updated in line with the company's third-quarter report for 2025, which has already been disclosed [1] Group 2 - The issuance of A-shares is subject to approval by the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, indicating uncertainty regarding the approval process and timeline [2] - The company will fulfill its information disclosure obligations based on the progress of this matter, urging investors to make cautious decisions and be aware of investment risks [2]